IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors

Leukemia

Volumn 28, Issue 8, 2014, Pages 1647-1656

  Jourdan, M ^a   Cren, M ^a   Robert, N ^b   Bollore K ^b   Fest, T ^c,d   Duperray, C ^a,b   Guilloton, F ^d   Hose, D ^e,f   Tarte, K ^c,d   Klein, B ^a,b,g  

^a HÔPITAL SAINT ELOI   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Nationales Centrum fur Tumorerkrankungen   (Germany)

^g UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B-CELL ACTIVATION FACTOR RECEPTOR; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CXCL12; HUMANS; INTERLEUKIN-6; NF-KAPPA B; PLASMA CELLS; TRANSCRIPTOME; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84905715990     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.61     Document Type: Article

References (56)

1. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KGC, Dörner T et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741-750.
2. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood 2010; 115: 3772-3775.
3. Terstappen L, Steen J, Seger-Nolten MJ, Loken MR. Identification and characterization of plasma cells in normal bone marrow by high resolution flow cytometry. Blood 1990; 9: 1739-1747.
4. Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol 2011; 32: 595-602.
5. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20: 707-718.
6. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 2013; 251: 177-188.
7. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001; 194: 45-56.
8. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24: 203-215.
9. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam K-P et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180: 3655-3659.
10. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009; 114: 5173-5181.
11. Huard B, McKee T, Bosshard C, Durual S, Matthes T, Myit S et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008; 118: 2887-2895.
12. Moreaux J, Sprynski A-C, Dillon SR, Mahtouk K, Jourdan M, Ythier A et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 2009; 83: 119-129.
13. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, VIta N et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Heamatol 1996; 94: 318-323.
14. Belnoue E, Tougne C, Rochat AF, Lambert PH, Pinschewer DD, Siegrist CA. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. J Immunol 2012; 188: 1283-1291.
15. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
16. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrowderived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002; 169: 4213-4221.
17. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171: 1684-1690.
18. Mesin L, Di Niro R, Thompson KM, Lundin KEA, Sollid LM. Long-lived plasma cells from human small intestine biopsies secrete immunoglobulins for many weeks in vitro. J Immunol 2011; 187: 2867-2874.
19. Mahtouk K, Moreaux J, Hose D, Rème T, Meissner T, Jourdan M et al. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 2010; 10: 198.
20. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-274.
21. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2009; 113: 2461-2469.
22. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010; 95: 1016-1020.
23. Geffroy-Luseau A, Jégo G, Bataille R, Campion L, Pellat-Deceunynck C. Osteoclasts support the survival of human plasma cells in vitro. Int Immunol 2008; 20: 775-782.
24. Cocco M, Stephenson S, Care MA, Newton D, Barnes NA, Davison A et al. In vitro generation of long-lived human plasma cells. J Immunol 2012; 189: 5773-5785.
25. Amé-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007; 109: 693-702.
26. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol 2011; 187: 3931-3941.
27. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V et al. A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics 2008; 9: 16.
28. Le Carrour T, Assou S, Tondeur S, Lhermitte L, Lamb N, Reme T et al. Amazonia!: an online resource to google and visualize public human whole genome expression data. Open Bioinformatics J 2010; 4: 5-10.
29. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
31. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JDJ, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614-4626.
32. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006; 18: 263-275.
33. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130.
34. Mahévas M, Patin P, Huetz F, Descatoire M, Cagnard N, Bole-Feysot C et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest 2012; 123: 432-442.
35. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363-372.
36. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23: 367-386.
37. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002; 99: 2154-2161.
38. Kallies A. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. J Exp Med 2004; 200: 967-977.
39. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003; 4: 321-329.
40. Rodrí guez-Bayona B, Ramos-Amaya A, López-Blanco R, Campos-Caro A, Brieva JA. STAT-3 activation by differential cytokines is critical for human-generated plasma cell survival and Ig secretion. J Immunol 2013; 191: 4996-5004.
41. Winter O, Moser K, Mohr E, Zotos D, Kaminski H, Szyska M et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 2010; 116: 1867-1875.
42. Tsai C-M, Chiu Y-K, Hsu T-L, Lin I-Y, Hsieh S-L, Lin K-I. Galectin-1 promotes immunoglobulin production during plasma cell differentiation. J Immunol 2008; 181: 4570-4579.
43. Anginot A, Espeli M, Chasson L, Mancini SJC, Schiff C. Galectin 1 modulates plasma cell homeostasis and regulates the humoral immune response. J Immunol 2013; 190: 5526-5533.
44. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005; 105: 1614-1621.
45. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-2011.
46. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157.
47. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumorpropagating cells in multiple myeloma. Blood 2013; 121: 318-328.
48. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116: e56-e65.
49. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
50. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 2012; 97: 622-630.
51. Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF et al. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS One 2012; 7: e42161.
52. Kassambara A, Schoenhals M, Moreaux J, Veyrune J-L, Rème T, Goldschmidt H et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One 2013; 8: e62752.
53. Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D et al. Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma. Haematologica 2013; 98: 1442-1449.
54. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
55. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009; 114: 128-143.
56. Schoenhals M, Frecha C, Bruyer A, Caraux A, Veyrune JL, Jourdan M et al. Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins. Leukemia 2012; 26: 1663-1670.